Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $9.20.

Several brokerages have issued reports on PYXS. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price target on shares of Pyxis Oncology in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research report on Wednesday.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $1.21 on Friday. The firm has a market cap of $74.52 million, a P/E ratio of -1.17 and a beta of 1.11. Pyxis Oncology has a fifty-two week low of $0.99 and a fifty-two week high of $6.18. The firm has a 50 day simple moving average of $1.33 and a 200 day simple moving average of $2.35.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01. The firm had revenue of $16.15 million for the quarter. On average, sell-side analysts expect that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Trading of Pyxis Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its position in Pyxis Oncology by 53.8% during the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock worth $4,650,000 after buying an additional 1,043,228 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Pyxis Oncology during the 3rd quarter valued at $1,405,000. Ridgeback Capital Investments L.P. acquired a new stake in shares of Pyxis Oncology during the 4th quarter worth $560,000. State Street Corp raised its stake in Pyxis Oncology by 28.0% in the third quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after purchasing an additional 208,344 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Pyxis Oncology during the fourth quarter worth about $228,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.